AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Investingnews

Published November 9, 2026

Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for ...

Read the full story at Investingnews

Psychedelics Market Trends: H1 2026 Review and Forecast. The psychedelic medicine market is moving swiftly from speculative research mode toward an.

Post on X

Share this story

Surfaced by 2 Google Alerts

Psychedelics
Psychedelic press release